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EDITORIAL
Fibromyalgia: Where Are We a Decade After the American College of
Rheumatology Classification Criteria Were Developed?
Leslie J. Crofford1 and Daniel J. Clauw2
The American College of Rheumatology (ACR)
published classification criteria for fibromyalgia (FM) in
1990 (1). These criteria allow investigators around the
world to investigate mechanisms of symptom expression
in FM with assurance that research subjects share the
presence of chronic widespread pain and evidence of
altered pain processing, as demonstrated by the pres-
ence of tender points. With publication of the classifica-
tion criteria, the ACR assumed a leadership position in
research into basic mechanisms underlying FM symp-
toms and management of patients with FM. What
progress has been made in the decade since the ACR
classification criteria were developed?
A strength of the criteria from a research stand-
point is that FM patients meeting the ACR classification
criteria are at the extreme end of the spectrum of pain
and tenderness. As a result, a number of studies have
demonstrated important alterations in pain processing
in FM. These studies use subjective ratings of experi-
mental pain paradigms as well as objective demonstra-
tion of an altered central representation of painful
stimuli.
Petzke et al demonstrated that patients with FM
had low mechanical and thermal pain thresholds regard-
less of whether the stimulus was presented in a predict-
able, ascending manner (as with tender point determi-
nations or dolorimetery) or randomly (2). These data
suggest that, compared with healthy individuals, FM
patients do not rate pain stimuli higher because of
psychological hypervigilance or “expectancy.” Staud et al
showed that patients with FM exhibit altered temporal
summation of pain stimuli administered as a thermal
stimulus to skin or as a mechanical stimulus to muscle
(3,4). The results of these studies suggest a parallel
between the human condition of FM and the “wind-up”
phenomenon that leads to hyperalgesia and has been
extensively studied in animal models (5).
Other data corroborating the veracity of FM
patients’ descriptions of pain have been collected using
paradigms that are not dependent on subjective reports
by patients. For example, Lorenz et al demonstrated
altered laser-evoked potentials as objective representa-
tion of the central nervous system (CNS) response to
cutaneous stimulation (6). Patients with FM were shown
by Mountz et al and by Cianfrini et al to have reduced
thalamic blood flow under resting conditions (a finding
observed in other chronic pain states) and altered re-
sponses to mechanical pain stimuli (7,8). Finally, Grant
et al demonstrated that increased blood flow to brain
regions known to receive pain input correlates with the
intensity of perceived pain rather than the absolute level
of the stimulus (9).
All these data arguably complement the most
consistent biologic finding supporting aberrant central
pain transmission in FM—the 3-fold higher concen-
trations of substance P in cerebrospinal fluid (CSF) of
FM patients compared with those in the CSF of normal
controls (10–13). Taken together, the data on pain
processing in FM demonstrate that the central represen-
tation of pain correlates with patient reports of pain, and
that purely behavioral or psychological factors are not
primarily responsible for the pain and tenderness seen
in FM.
The ACR classification criteria focus only on
pain, however, and disregard other important FM symp-
toms, including fatigue, cognitive disturbance, sleep
disturbance, and psychological distress. If one takes a
more general view of FM that includes these symptoms
and commonly associated syndromes (e.g., chronic fa-
tigue syndrome, irritable bowel syndrome, and depres-
sion), then the ACR criteria fail to capture the essence
of the FM syndrome. When research subjects are iden-
tified using the ACR criteria, there is greater variability
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in studies of physiologic mechanisms other than pain
processing. For example, studies of the hypothalamic–
pituitary–adrenal (HPA) axis must consider the impact
of comorbid conditions (e.g., mood disorders and
chronic fatigue syndrome, neither of which is an exclu-
sion to the diagnosis of FM) that might independently
alter HPA axis activity. Nevertheless, studies of the HPA
axis (14–17) and the sympathetic nervous system (18–22)
have demonstrated alterations in most instances. It is
plausible that alterations of these stress-response sys-
tems identify a population vulnerable to the develop-
ment of FM. Alternatively, altered neuroendocrine axis
activity could cause or occur as a consequence of some
FM symptoms. It is likely that these neurobiologic
alterations are shared with other poorly understood
somatic syndromes and psychiatric disorders that fre-
quently occur concurrently with FM.
In this issue of Arthritis & Rheumatism, Paiva et al
describe an important neuroendocrine disturbance seen
in FM patients. This study represents an extension of
previous work by this group demonstrating that serum
levels of insulin-like growth factor 1 are diminished in a
substantial percentage of FM patients, and that treating
these individuals with human recombinant growth hor-
mone (GH) leads to improvement of symptoms (23,24).
The present study demonstrates that failure of the GH
axis to respond to an exercise stress is attributable to
increased levels of somatostatin. Somatostatin tone is
critically important to physiologic alteration in GH
secretion, both acutely (e.g., exercise) and chronically
(e.g., aging, obesity). Although the study by Paiva et al
does not determine the reason for increased somatosta-
tin tone, all of the possibilities suggested by the authors
include regulatory mechanisms localized to the CNS and
revolving around an altered physiologic response to
stress. Thus, the results of this study provide additional
evidence that central mechanisms are involved in the
pathophysiology of the FM syndrome.
In addition to neurobiologic mechanisms, behav-
ioral factors play a role in symptom expression in many
FM patients. A typical pattern is that as a result of pain
and other symptoms of FM, individuals begin to function
less well in their various roles. They may have difficulties
with spouses, children, and work inside or outside the
home, which exacerbate symptoms and lead to maladap-
tive illness behaviors. Such behaviors include isolation,
cessation of pleasurable activities, and reductions in
activity and exercise. In the worst cases, patients become
involved with disability and compensation systems,
which almost ensures that they will not improve (25).
The complex interaction of biologic and behav-
ioral mechanisms is not, however, unique to FM. Nonbio-
logic factors play a prominent role in symptom expres-
sion in all rheumatic diseases. In fact, in conditions such
as rheumatoid arthritis and osteoarthritis (OA), nonbio-
logic factors such as level of formal education, coping
strategies, and socioeconomic variables account for
more of the variance in pain reporting and disability
than do biologic factors, such as joint space width or
erythrocyte sedimentation rate (25,26). Why, then,
should we be surprised that nonbiologic factors play a
significant role in FM?
Nevertheless, many rheumatologists express
enormous frustration aimed specifically at FM patients
or the FM “construct.” The most simplistic reason for
this frustration may be psychological distress on the part
of patients, physicians, or both. Patients with FM display
higher average levels of distress than do individuals with
other rheumatic disorders (27). Previous unsatisfactory
interactions with the health care system may increase the
likelihood of an adversarial relationship between patient
and physician. Distress on the part of physicians is likely,
because mechanisms underlying FM symptoms are
poorly understood and are outside the realm of mecha-
nisms traditionally studied by rheumatologists (e.g., im-
munology, inflammation, connective tissue biology). In
addition, current pharmacologic therapies are often
ineffective, nonpharmacologic therapies require time to
implement, and dealing with contentious issues sur-
rounding FM such as disability compensation or litiga-
tion is frustrating and counterproductive.
Population-based studies have demonstrated that
chronic pain and fatigue syndromes affect huge numbers
of individuals; the results are similar regardless of where
the studies are performed or what labels are used to
identify these individuals (28). It has been suggested that
our specialty should exclude treatment of FM patients
for the stated reason that there are not enough rheuma-
tologists to treat the diseases we are uniquely qualified
to manage. However, musculoskeletal pain is properly
evaluated by rheumatologists, using our specialized
knowledge to facilitate the correct diagnosis and insti-
tute a treatment plan. What is, perhaps, even more
germane is the fact that many of our patients with
inflammatory arthritides, connective tissue diseases,
OA, and regional soft tissue disorders also manifest
symptoms of FM. Studies have demonstrated that 20%
of individuals with nearly any type of rheumatic disease
will meet ACR criteria for FM (29). An even higher
percentage will have some elements of pain or other
somatic symptoms not explained by immune activation
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or tissue damage or will manifest behaviors that play a
prominent role in symptom expression.
Rheumatologists have established a leadership
position in research on the mechanisms underlying FM
symptoms and the most appropriate treatments for FM
patients. That position can be used to educate patients
and primary care physicians and dictate how this disor-
der is best managed. Even if a rheumatologist is required
to make the initial diagnosis of FM, treatment can be
implemented effectively by primary care physicians.
Abandoning our leadership position is not likely to
further basic research on the mechanisms underlying
FM symptoms, decrease the number of individuals with
chronic widespread musculoskeletal pain, or improve
management of these patients.
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